Lenvima (lenvatinib) — CareFirst (Caremark)

Initial criteria

• Metastatic or unresectable cutaneous melanoma that has progressed following treatment with an anti-PD-1/PD-L1-based therapy
• AND used in combination with pembrolizumab (Keytruda)

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months